105 lines
3.4 KiB
YAML
105 lines
3.4 KiB
YAML
|
abstract: 'Background: Anti-cancer cytotoxic treatments like platinum-derived
|
||
|
|
|
||
|
|
compounds often show low therapeutic efficacy, high-risk side effects
|
||
|
|
|
||
|
|
and resistance. Hence, targeted treatments designed to attack only
|
||
|
|
|
||
|
|
tumour cells avoiding these harmful side effects are highly needed in
|
||
|
|
|
||
|
|
clinical practice. Due to this, precision oncology has arisen as an
|
||
|
|
|
||
|
|
approach to specifically target alterations present only in cancer
|
||
|
|
|
||
|
|
cells, minimising side effects for patients. It involves the use of
|
||
|
|
|
||
|
|
molecular biomarkers present in each kind of tumour for diagnosis,
|
||
|
|
|
||
|
|
prognosis and treatment. Since these biomarkers are specific for each
|
||
|
|
|
||
|
|
cancer type, physicians use them to stratify, diagnose or take the best
|
||
|
|
|
||
|
|
therapeutic options for each patient depending on the features of the
|
||
|
|
|
||
|
|
specific tumour.
|
||
|
|
|
||
|
|
Aim: This review aims to describe the current situation, limitations,
|
||
|
|
|
||
|
|
advantages and perspectives about precision oncology in Latin America.
|
||
|
|
|
||
|
|
Main body: For many years, many biomarkers have been used in a clinical
|
||
|
|
|
||
|
|
setting in developed countries. However, in Latin American countries,
|
||
|
|
|
||
|
|
their broad application has not been affordable partially due to
|
||
|
|
|
||
|
|
financial and technical limitations associated with precarious health
|
||
|
|
|
||
|
|
systems and poor access of low-income populations to quality health
|
||
|
|
|
||
|
|
care. Furthermore, the genetic mixture in Latin American populations
|
||
|
|
|
||
|
|
could generate differences in treatment responses from one population to
|
||
|
|
|
||
|
|
another (pharmacoethnicity) and this should be evaluated before
|
||
|
|
|
||
|
|
establishing precision therapy in particular populations. Some research
|
||
|
|
|
||
|
|
groups in the region have done a lot of work in this field and these
|
||
|
|
|
||
|
|
data should be taken as a starting point to establish networks oriented
|
||
|
|
|
||
|
|
to finding clinically useful cancer biomarkers in Latin American
|
||
|
|
|
||
|
|
populations.
|
||
|
|
|
||
|
|
Conclusion: Latin America must create policies allowing excluded
|
||
|
|
|
||
|
|
populations to gain access to health systems and next generation
|
||
|
|
|
||
|
|
anti-cancer drugs, i.e. high-cost targeted therapies to improve
|
||
|
|
|
||
|
|
survival. Also, cancer clinical research must be oriented to establish
|
||
|
|
|
||
|
|
cancer biomarkers adapted to specific populations with different
|
||
|
|
|
||
|
|
ethnicity, allowing the improvement of patient outcomes.'
|
||
|
|
affiliation: 'Orue, A (Corresponding Author), IVIC, Ctr Microbiol, Tumor Cell Biol
|
||
|
|
Lab, Caracas 1020A, Venezuela.
|
||
|
|
|
||
|
|
Calderon-Auaricio, Ali; Orue, Andrea, IVIC, Ctr Microbiol, Tumor Cell Biol Lab,
|
||
|
|
Caracas 1020A, Venezuela.'
|
||
|
|
article-number: '920'
|
||
|
|
author: Calderon-Auaricio, Ali and Orue, Andrea
|
||
|
|
author-email: andreaorue@gmail.com
|
||
|
|
author_list:
|
||
|
|
- family: Calderon-Auaricio
|
||
|
|
given: Ali
|
||
|
|
- family: Orue
|
||
|
|
given: Andrea
|
||
|
|
da: '2023-09-28'
|
||
|
|
doi: 10.3332/ecancer.2019.920
|
||
|
|
files: []
|
||
|
|
issn: 1754-6605
|
||
|
|
journal: ECANCERMEDICALSCIENCE
|
||
|
|
keywords: 'precision oncology; biomarkers; cancer; targeted therapy; access to
|
||
|
|
|
||
|
|
health care; Latin America'
|
||
|
|
keywords-plus: 'CELL LUNG-CANCER; ANDROGEN RECEPTOR; PERSONALIZED MEDICINE; OPEN-LABEL;
|
||
|
|
|
||
|
|
METHYLATION; EPIGENOMICS; MUTATIONS; THERAPY; DRUGS; EGFR'
|
||
|
|
language: English
|
||
|
|
month: APR 3
|
||
|
|
number-of-cited-references: '78'
|
||
|
|
orcid-numbers: Calderon-Aparicio, Ali/0000-0003-0656-1434
|
||
|
|
papis_id: fc9d7da5e3f031b464597b9888d132ba
|
||
|
|
ref: Calderonauaricio2019precisiononcology
|
||
|
|
times-cited: '7'
|
||
|
|
title: 'Precision oncology in Latin America: current situation, challenges and perspectives'
|
||
|
|
type: Article
|
||
|
|
unique-id: WOS:000464006000001
|
||
|
|
usage-count-last-180-days: '0'
|
||
|
|
usage-count-since-2013: '2'
|
||
|
|
volume: '13'
|
||
|
|
web-of-science-categories: Oncology
|
||
|
|
year: '2019'
|